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tient was 33 000 SFr (interquartile range 27211–43476).
Median age of the patients was 63 years (interquartile
range 55–70). We found that the following preoperative
characteristics were significantly associated with cost: age
(P  0.001), preoperative cardiac diagnosis (P  0.001),
preoperative risk scores (P  0.0001). The bivariate analy-
sis showed a highly significant correlation between intra-
operative variables, except aorta clamp time (P  0.0001).
All postoperative variables turned out to be significantly
predictive of costs (P  0.0001). In order to predict the
costs we developed a linear model based on significant pre-,
intra- and postoperative variables. The model predicted
hospital costs (Y) for patients based on EuroSCORE (X1),
operation time (X2), intubation time (X3) and postoper-
ative infection (X4). Median length of stay was 10 days
(interquartile range 8–12) in the general ward and 1 day
(interquartile range 1–3) in the intensive care unit. CON-
CLUSIONS: Hospital costs are closely related to the pre-
operative risk scores, intraoperative variables and occur-
rence of postoperative complications, which means that
this model can prospectively identify patients at the first
postoperative day, who are at risk for excess of costs.
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OBJECTIVES: To compare the treatment costs of amlo-
dipine versus enalapril in the treatment of mild to moder-
ate hypertension in France, Italy, Germany, Spain and
Sweden. METHODS: A post-hoc analysis was performed
by examining the patient-level data from a one year, dou-
ble blind clinical trial of amlodipine (n  231) versus
enalapril (n  230). We determined the frequency and
dosage of antihypertensives administered longitudinally
in both treatment arms. The analysis also compared the
adverse event profiles and efficacy rates in each treatment
group. Ex-factory costs of amlodipine, enalapril, and the
diuretic, hydrochlorothiazide (HCTZ), were obtained for
all countries. The net costs of treatment were calculated
within trial phases and throughout the 50-week trial pe-
riod. RESULTS: In all the countries evaluated, the aver-
age treatment costs in the amlodipine group were less ex-
pensive than those in the enalapril group producing a
cost savings over the trial duration ranging from 2%
($2.81) in Spain to 32% ($81) in France. The mean final
visit drug dosages per patient were 7.2 mg/day for amlo-
dipine and 28 mg/day for enalapril. The total reduction
in sitting DBP was not significantly different between
treatment groups; however, significantly more patients (P 
0.05) in the enalapril group (n  46, 20%) required the
use of HCTZ to attain control of DBP than in the amlo-
dipine group (n  27, 11.7%). Finally, there were no sig-
nificant differences (P  0.05) in adverse events between
groups. CONCLUSION: Healthcare providers should favor
utilization of amlodipine over enalapril as a less expen-
sive and equally effective means of achieving blood pres-
sure control in the mild to moderate hypertensive popula-
tions of Europe.
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OBJECTIVE: To assess direct medical costs in patients
with varicose veins (VV) and the association between VV
and costs in patients with venous disorders. METHODS:
416 patients included in the VEINES cohort study in Bel-
gium were followed for a mean of 11.34 months, with
health service utilization measured three times from phy-
sicians and patients. Items measured included consulta-
tions to physicians and health professionals, diagnostic tests,
drugs, compression material and interventions (sclero-
therapy, surgery, wound care, physiotherapy). Total costs
(T) and costs for patients (P) were valued. RESULTS:
Age and gender-standardized one-year adjusted mean
costs for all patients with VV were US$311.24 (T) and
$107.36 (P). Interventions represented 46.2% of T costs
and 14.5% of P costs, whereas drug costs represented
17.1% and 22.6% respectively. In patients without VV
(only symptoms or telangiectasia), T and P costs were
US$134.72 and $75.67. Costs in patients with VV alone
were US$304.9 (T) and $81.8 (P). Patients with VV and
ulcer had the lowest costs (T: 189.1, P: 111.2) due to the
small number of surgical interventions. In semilog covari-
ance model adjusted for other venous disorders and de-
terminants of health service utilization in all patients with
venous disorders, a cost ratio (CR) of 2.32 (95% CI: 1.25
to 4.30) was observed for patients with VV vs. without
VV. Other main cost determinant was baseline measure
of disease-specific quality of life (VEINES-QOL) with in-
verse relationship (CR for highest vs. lowest QoL scores:
0.14, 95% CI: 0.07–0.27). CONCLUSIONS: Costly in-
terventions (e.g. surgery) are predominantly used by pa-
tients with VV alone for cosmetic reason, and with VV
and skin changes possibly for ulcer prevention. Disease-
specific QoL (VEINES-QOL) could be an important out-
come in baseline evaluation of clinical and pharmacoeco-
nomic studies on VV, as it was associated with level of
health services utilization over 12 months.
